Current phase-I clinical trials therefore assess the safety and dose-escalation options for the use of phenformin in combination with BRAFi and MEKi therapy in metastatic melanoma (NCT03026517), as well the combination of metformin and temsirolimus, an mTOR inhibitor, in advanced cancers (NCT01529593). The gene discussed is MTOR; the disease is cancer.